Rho kinase inhibition with fasudil in the SOD1G93A mouse model of amyotrophic lateral sclerosis-symptomatic treatment potential after disease onset

Frontiers in Pharmacology

Volumn 8, Issue JAN, 2017, Pages

  Günther, René ^a,b   Balck, Alexander ^a,c   Koch, Jan C ^a   Nientiedt, Tobias ^d   Sereda, Michael ^d,e   Bähr, Mathias ^a,f   Lingor, Paul ^a,f   Tönges, Lars ^a,f,g  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^e Department of Clinical Neurophysiology ^*  (Germany)

^f Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB)   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

Author keywords

Fasudil; Mouse model of ALS; Neuroprotection; ROCK; SOD1

Indexed keywords

FASUDIL; RHO KINASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR ASSESSMENT; BODY WEIGHT; CELL INFILTRATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOTONEURON; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROLOGIC EXAMINATION; NONHUMAN; OVERALL SURVIVAL; ROTAROD TEST; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT DURATION;

EID: 85012104120     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00017     Document Type: Article

References (48)

1. Alves, C. J., de Santana, L. P., dos Santos, A. J., de Oliveira, G. P., Duobles, T., Scorisa, J. M., et al. (2011). Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Res. 1394, 90-104. doi: 10.1016/j.brainres.2011.02.060
2. Benatar, M. (2007). Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 26, 1-13. doi: 10.1016/j.nbd.2006.12.015
3. Bermel, C., Tonges, L., Planchamp, V., Gillardon, F., Weishaupt, J. H., Dietz, G. P., et al. (2009). Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol. Cell. Neurosci.42, 427-437. doi: 10.1016/j.mcn.2009.09.005
4. Bowerman, M., Beauvais, A., Anderson, C. L., and Kothary, R. (2010). Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet.19, 1468-1478. doi: 10.1093/hmg/ddq021
5. Bowerman, M., Murray, L. M., Boyer, J. G., Anderson, C. L., and Kothary, R. (2012). Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 10:24. doi: 10.1186/1741-7015-10-24
6. Brites, D., and Vaz, A. R. (2014). Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front. Cell. Neurosci.8:117. doi: 10.3389/fncel.2014.00117
7. Brooks, B. R., Miller, R. G., Swash, M., and Munsat, T. L. (2000). El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Sclerosis Other Motor Neuron Disord. 1, 293-299.
8. Choi, C. I., Lee, Y. D., Gwag, B. J., Cho, S. I., Kim, S. S., and Suh-Kim, H. (2008). Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J. Neurol. Sci. 268, 40-47. doi: 10.1016/j.jns.2007.10.024
9. Conti, A., Riva, N., Pesca, M., Iannaccone, S., Cannistraci, C. V., Corbo, M., et al. (2014). Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim. Biophys. Acta 1842, 99-106. doi: 10.1016/j.bbadis.2013.10.013
10. Crawley, J. N. (2008). Behavioral phenotyping strategies for mutant mice. Neuron57, 809-818. doi: 10.1016/j.neuron.2008.03.001
11. Gentry, E. G., Henderson, B. W., Arrant, A. E., Gearing, M., Feng, Y., Riddle, N. C., et al. (2016). Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration. J. Neurosci. 36, 1316-1323. doi: 10.1523/JNEUROSCI.2336-15.2016
12. Golko-Perez, S., Amit, T., Youdim, M. B., and Weinreb, O. (2016). Beneficial effects of multitarget iron chelator on central nervous system and gastrocnemius muscle in SOD1(G93A) transgenic ALS mice. J. Mol. Neurosci. 59, 504-510. doi: 10.1007/s12031-016-0763-2
13. Groeneveld, G. J., Van Muiswinkel, F. L., Sturkenboom, J. M., Wokke, J. H., Bär, P. R., and Van den Berg, L. H. (2004). Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. Brain Res. 1021, 128-131. doi: 10.1016/j.brainres.2004.06.024
14. Günther, R. (2015). Pharmacological Inhibition of Rho-Kinase in the Mouse Model of Amyotrophic Lateral Sclerosis. Dissertation, University of Göttingen, Göttingen.
15. Günther, R., Saal, K. A., Suhr, M., Scheer, D., Koch, J. C., Bahr, M., et al. (2014). The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice. Front. Neurosci. 8:304. doi: 10.3389/fnins.2014.00304
16. Günther, R., Suhr, M., Koch, J. C., Bahr, M., Lingor, P., and Tonges, L. (2012). Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS). J. Vis. Exp. 61:e3936. doi: 10.3791/3936
17. Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., et al. (1994). Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science264, 1772-1775. doi: 10.1126/science.8209258
18. Hattori, T., Shimokawa, H., Higashi, M., Hiroki, J., Mukai, Y., Tsutsui, H., et al. (2004). Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation109, 2234-2239. doi: 10.1161/01.CIR.0000127939.16111.58
19. Jacobs, M., Hayakawa, K., Swenson, L., Bellon, S., Fleming, M., Taslimi, P., et al. (2006). The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J. Biol. Chem. 281, 260-268. doi: 10.1074/jbc.M508847200
20. Léger, B., Vergani, L., Sorarù, G., Hespel, P., Derave, W., Gobelet, C., et al. (2006). Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J. 20, 583-585. doi: 10.1096/fj.05-5249fje
21. Li, M., Huang, Y., Ma, A. A., Lin, E., and Diamond, M. I. (2009). Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis. 36, 413-420. doi: 10.1016/j.nbd.2009.06.011
22. Li, M., Yasumura, D., Ma, A. A., Matthes, M. T., Yang, H., Nielson, G., et al. (2013). Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. PLoS ONE 8:e56026. doi: 10.1371/journal.pone.0056026
23. Lingor, P., Tönges, L., Pieper, N., Bermel, C., Barski, E., Planchamp, V., et al. (2008). ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain131, 250-263. doi: 10.1093/brain/awm284
24. Mancuso, R., Oliván, S., Mancera, P., Pastén-Zamorano, A., Manzano, R., Casas, C., et al. (2012). Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph. Lateral Sclerosis 13, 302-310. doi: 10.3109/17482968.2012.662688
25. Miana-Mena, F. J., Muñoz, M. J., Yagüe, G., Mendez, M., Moreno, M., Ciriza, J., et al. (2005). Optimal methods to characterize the G93A mouse model of ALS. Amyotroph. Lateral Sclerosis Other Motor Neuron Disord. 6, 55-62. doi: 10.1080/14660820510026162
26. Moloney, E. B., de Winter, F., and Verhaagen, J. (2014). ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 8:252. doi: 10.3389/fnins.2014.00252
27. Oliván, S., Calvo, A. C., Rando, A., Muñoz, M. J., Zaragoza, P., and Osta, R. (2015). Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Exp. Anim. 64, 147-153. doi: 10.1538/expanim.14-0077
28. Peters, O. M., Ghasemi, M., and Brown, R. H. Jr. (2015). Emerging mechanisms of molecular pathology in ALS. J. Clin. Invest. 125, 1767-1779. doi: 10.1172/JCI71601
29. Pfohl, S. R., Halicek, M. T., and Mitchell, C. S. (2015). Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: a meta-analysis. J. Neuromuscul. Dis. 2, 137-150. doi: 10.3233/JND-140068
30. Philips, T., and Robberecht, W. (2011). Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10, 253-263. doi: 10.1016/S1474-4422(11)70015-1
31. Planchamp, V., Bermel, C., Tönges, L., Ostendorf, T., Kügler, S., Reed, J. C., et al. (2008). BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity. Brain 131, 2606-2619. doi: 10.1093/brain/awn196
32. Robberecht, W., and Philips, T. (2013). The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248-264. doi: 10.1038/nrn3430
33. Rodriguez-Perez, A. I., Dominguez-Meijide, A., Lanciego, J. L., Guerra, M. J., and Labandeira-Garcia, J. L. (2013). Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol. Dis. 58, 209-219. doi: 10.1016/j.nbd.2013.06.004
34. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. doi: 10.1038/362059a0
35. Stewart, A., Sandercock, J., Bryan, S., Hyde, C., Barton, P. M., Fry-Smith, A., et al. (2001). The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol. Assess. 5, 1-97. doi: 10.3310/hta5020
36. Suzuki, Y., Shibuya, M., Satoh, S., Sugimoto, Y., and Takakura, K. (2007). A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 68, 126-131; discussion: 31-32. doi: 10.1016/j.surneu.2006.10.037
37. Takata, M., Tanaka, H., Kimura, M., Nagahara, Y., Tanaka, K., Kawasaki, K., et al. (2013). Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental amyotrophic lateral sclerosis models. Br. J. Pharmacol. 170, 341-351. doi: 10.1111/bph.12277
38. Tatenhorst, L., Eckermann, K., Dambeck, V., Fonseca-Ornelas, L., Walle, H., Lopes da Fonseca, T., et al. (2016). Fasudil attenuates aggregation of alpha-synuclein in models of Parkinson's disease. Acta Neuropathol. Commun. 4:39. doi: 10.1186/s40478-016-0310-y
39. Tönges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, E. M., et al. (2012). Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 135, 3355-3370. doi: 10.1093/brain/aws254
40. Tönges, L., Gunther, R., Suhr, M., Jansen, J., Balck, A., Saal, K. A., et al. (2014). Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 62, 217-232. doi: 10.1002/glia.22601
41. Tönges, L., Koch, J. C., Bahr, M., and Lingor, P. (2011). ROCKing Regeneration: rho kinase inhibition as molecular target for neurorestoration. Front. Mol. Neurosci. 4:39. doi: 10.3389/fnmol.2011.00039
42. Turner, B. J., and Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85, 94-134. doi: 10.1016/j.pneurobio.2008.01.001
43. Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chio, A., de Carvalho, M., et al. (2013). Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12, 310-322. doi: 10.1016/S1474-4422(13)70036-X
44. Vucic, S., Rothstein, J. D., and Kiernan, M. C. (2014). Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 37, 433-442. doi: 10.1016/j.tins.2014.05.006
45. Weydt, P., Hong, S. Y., Kliot, M., and Moller, T. (2003). Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 14, 1051-1054. doi: 10.1097/00001756-200305230-00029
46. Zhao, Y. F., Zhang, Q., Xi, J. Y., Li, Y. H., Ma, C. G., and Xiao, B. G. (2015). Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease. J. Neurol. Sci. 353, 28-37. doi: 10.1016/j.jns.2015.03.022
47. Zhao, Y., Zhang, Q., Xi, J., Xiao, B., Li, Y., and Ma, C. (2015). Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/beta-catenin dependent pathways in a mice model of Parkinson's disease. Int. J. Clin. Exp. Pathol. 8, 2354-2364. Available online at: www.ijcep.com/ISSN:1936-2625/IJCEP0005365
48. Zielasek, J., Martini, R., and Toyka, K. V. (1996). Functional abnormalities in P0-deficient mice resemble human hereditary neuropathies linked to P0 gene mutations. Muscle Nerve 19, 946-952. doi: 10.1002/(SICI)1097-4598(199608)19:8<946::AID-MUS2>3.0.CO;2-8